Pune: Phase 2 human trial of Oxford Covid-19 vaccine may start tomorrow

Doses of the potential coronavirus

vaccine developed by researchers at Oxford University arrived at the Bharti Vidyapeeth's Medical College here for phase-2 human trials on Tuesday, an official said.

The trial may begin from Wednesday, said a top official of the institute, one of the 17 sites selected for the phase 2 human trials in the country by Serum Institute of India (SII).

"To start with we have identified five volunteers who will undergo COVID-19 and antibodies test. Those whosereports are negative will be shortlisted for vaccination on Wednesday," said Dr Sanjay Lalwani, Medical Director, Bharti Vidyapeeth's Medical College and Hospital and Research Centre.

He said the hospital has been given a target of enlisting 300 to 350 volunteers. Those chosen for receiving a dose of vaccine will be in the age group of 18 to 99 years, he told PTI.

Dr Jeetendra Oswal, deputy medical director of the hospital, said after they are administered the vaccine, the volunteers will be monitored as per the standard trial protocol.

The other hospitals where trials are to be conducted include B J Medical College Hospital in Pune, AIIMS Delhi, Rajendra MemorialResearch Institute of Medical Sciences in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh,Nehru Hospital in Gorakhpur and Andhra Medical College in Visakhapatnam.

SII, the world's largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel